Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3121–3144 of 13,629 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatoses Clear all

Conditions: Atopic Dermatitis
Interventions: Tralokinumab + TCS, Placebo + TCS; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 6 Months to 11 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 15
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • Palo Alto, California + 11 more

Conditions: Opioid Use, Opioid Prescribing, Dispensing, and Patient Use
Interventions: Opioid Package Prototype (OPP), Usual Care (standard amber vial); Other
Lead sponsor: UConn Health; Other
Eligibility: 18 Years and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Acute Hepatic Porphyria, Hepatic Porphyrias, Acute Intermittent Porphyria (AIP), Hereditary Coproporphyria (HCP), Variegate Porphyria (VP), ALA Dehydratase Deficient Porphyria (ADP), Porphyria Acute
Interventions: Not listed
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 16 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 12
States / cities: Pasadena, California • Jacksonville, Florida • Margate, Florida + 9 more

Conditions: Hidradenitis Suppurativa
Interventions: Verbal consultation, Written Action Plan; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 100 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Brain Metastases, Breast Cancer, Metastatic Breast Cancer
Interventions: BKM120, capecitabine, Trastuzumab; Drug
Lead sponsor: US Oncology Research; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Multiple Locations, Texas

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo, Tdap vaccine, PPS vaccine; Drug · Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 47
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 40 more

Conditions: Acne Vulgaris, Acne
Interventions: HBKB Capsule, HBKB Supplement Vehicle; Dietary Supplement · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 35 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Acne, Premenstrual Syndrome
Interventions: Skincare Routine, MINDBODYSKIN Supplement; Other · Dietary Supplement
Lead sponsor: Clearstem Skincare; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes
Interventions: Carboplatin, Paclitaxcel, Pembrolizumab; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2034
U.S. locations: 2
States / cities: Syracuse, New York • Charleston, South Carolina

Conditions: Advanced or Metastatic Breast Cancer
Interventions: Trastuzumab deruxtecan, Capecitabine, Paclitaxel, Nab-Paclitaxel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 105 Years
Enrollment: 866 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 27
States / cities: Scottsdale, Arizona • Springdale, Arkansas • Duarte, California + 23 more

Conditions: Diabetic Foot Ulcer, Wagner Grade 1 - 2, Chronic Wound, Open Wound
Interventions: ELU42 Topical Spray; Drug
Lead sponsor: Eluciderm Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: O'Fallon, Illinois • Springfield, Illinois • Oradell, New Jersey + 1 more

Conditions: Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma
Interventions: NX-1607, Paclitaxel; Drug
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 10
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 7 more

Conditions: Breast Neoplasms
Interventions: Ultrasound- Virtual Touch Tissue Imaging Quantification; Device
Lead sponsor: Heidelberg University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Youngstown, Ohio

Conditions: Melanoma
Interventions: XL888, Vemurafenib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Psoriasis
Interventions: DFD01 Spray, Comp01 Lotion, Vehicle Lotion, Vehicle Spray; Drug
Lead sponsor: Primus Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 40
States / cities: Mobile, Alabama • Hot Springs, Arkansas • Encinitas, California + 35 more

Conditions: Chronic Radiation Dermatitis
Interventions: Fractional CO2 laser treatment, No treatment; Device · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Psoriasis, Plaque Psoriasis, Psoriasis Vulgaris
Interventions: Hypericin; Drug
Lead sponsor: Soligenix; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Breast Cancer
Interventions: ChemoFX Assay; Other
Lead sponsor: Precision Therapeutics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 28
States / cities: Long Beach, California • Los Angeles, California • Miami, Florida + 21 more

Conditions: Atopic Dermatitis
Interventions: A written Eczema Action Plan (EAP); Other
Lead sponsor: Dermatology & Aesthetics of Wicker Park; Other
Eligibility: Not listed
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pancreas Cancer, Melanoma
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Cancer
Interventions: tamoxifen citrate, gene expression analysis, protein expression analysis, immunoenzyme technique, laboratory biomarker analysis; Drug · Genetic · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Cancer, Immunotherapy, Advanced Solid Tumors Cancer, Bladder Cancer, TNBC, Triple Negative Breast Cancer, Colorectal Cancer, DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer, NSCLC (Non-small-cell Lung Cancer), Skin Cancer, Melanoma (Skin Cancer)
Interventions: Biopsy; Procedure
Lead sponsor: Elephas; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2038
U.S. locations: 8
States / cities: Fort Smith, Arkansas • Frederick, Maryland • Springfield, Missouri + 4 more

Conditions: Breast Cancer
Interventions: Single fraction of 7 Gy; Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Metastatic Melanoma
Interventions: Aldesleukin: All Patients, Nivolumab: Cohort 1 (Cutaneous), Nivolumab: Cohort 2 (Ocular), Ipilimumab: Cohort 2 (Ocular); Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Burnsville, Minnesota

Search by objective public record fields.

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

Opioid Package Prototype (OPP)

INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP

Hidradenitis Suppurativa Written Action Plan

STAR Cape+BKM120 MBC With Brain Met

A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

Skin Hydration in Persons With Acne After Dietary Supplementation With Botanical Antioxidants

An RCT Evaluating the Efficacy of a Skincare Routine and Acne Supplement on Improving Acne and Other Symptoms of PMS

A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers

A Study of NX-1607 in Adults With Advanced Malignancies

Evaluation of Virtual Touch Tissue Imaging Quantification (VTIQ - 2D-SWE) in the Assessment of BI-RADS® 3 and 4 Lesions

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis

Pilot Study of the Effect of Laser on Reversing Chronic Radiation Injury

Topical SGX302 for Mild-to-Moderate Psoriasis

Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer

Eczema Action Plan Improves Patient and Caregiver Understanding and Perception of Atopic Dermatitis Management

Two Cancers, One Gene. Why Some People in Families Develop Melanoma or Pancreas Cancer, While Still Others Never Develop Cancer.

Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

Study of Preoperative Boost Radiotherapy

Radiation and Combination Immunotherapy for Melanoma